Supplementary Figure 1

0.0

0.5

1.0

1.5 Trip-br2

Ctrl LPS

Rel

ativ

e ex

pres

sion

/TBP

(A.U

.)

b �

Trans 1 Trans 2 Trans 3 0.0

0.1

0.2

0.3

0.4 iWAT adipocytes gWAT adipocytes

Trip-br2 transcripts

Nor

mal

ized

exp

ress

ion/

TBP

(A.U

.)

Trans 1 Trans 2 Trans 3 0.0

0.2

0.4

0.6 Trip-br2 transcripts iWAT gWAT

Nor

mal

ized

exp

ress

ion/

TBP

(A.U

.) a �

0

1

2

3

4 F4/80

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

SVF Adipose tissue

iWAT

SVF Adipose tissue

gWAT

c

SVF Adipose tissue 0

10

20

30

40 F4/80 CD

HFD *

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

gWAT

***

Supplementary Figure 1. TRIP-Br2 expression in WAT and adipocytes treated with LPS (a) qPCR analysis of TRIP-Br2 transcripts gene expression in gonadal (gWAT) or inguinal (iWAT) adipose tissues or isolated mature adipocyted from chow diet-fed mice (n=6 per group replicated twice). (b) qPCR analysis of TRIP-Br2 gene expression in 3T3-L1 differentiated adipocytes treated with vehicle or LPS for 24 h (n=4 per group). (c) qPCR analysis of F4/80 gene expression in gWAT or iWAT stromal-vascular-fraction (SVF) or adipose tissues from CD or HFD-fed mice (n=5 per group replicated twice). All qPCR data are normalized with TBP and presented as mean ± SEM. Two-tailed student t-test, *,p<0.05; **,p<0.01; ***,p<0.001.

Ctrl Tuni-6h Tuni-12h Tuni-18h

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.) Atf4

iWAT gWAT 0

2

4

6

8

10

*** ***

***

***

***

Bip

iWAT gWAT 0

1

2

3

4

5

*

* **

Chop

iWAT gWAT 0

2

4

6

8

10

* *

***

**

*

CD HFD

HFD+TUDCA

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

Chop Atf4 Xbp1s Creb3 0.0

0.5

1.0

1.5

2.0

2.5 ***

## * * *

a

b

c d

#

CD-4 wk

HFD-4 wk CD-8 wk HFD-8 wk

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

Chop Atf4 Xbp1s Creb3 0.0

0.5

1.0

1.5

2.0

2.5

* * * *

* ** *

Atf4 Ctrl Tuni

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

iWAT gWAT Liver Heart 0

1

2

3

*** ***

**

Bip

iWAT gWAT Liver Heart 0 1 2 3 4 5 8

10 12 14

*

*

***

iWAT gWAT Liver Heart 0 1 2 3 4 5

20 25 30 35 40

* *

** Chop

0

1

2

3 **

Human adipocytes-PPARγ2

**

Visceral SQ Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

f e e

gWAT iWAT 0.0 0.5 1.0 1.5 2.0 400 500 600 700 800

Pparγ

*** ***

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

0.0

0.5

1.0

1.5

2.0 100 200 300 400

**

Human adipocytes-AP2 Undifferentiated Differentiated

**

Visceral SQ Rel

ativ

e ex

pres

sion

/TBP

(A.U

.)

Supplementary Figure 2

Supplementary Figure 2. ER stress markers induced by chemical or high-fat diet qPCR analysis of ER stress markers gene expression in (a) tissues harvested from mice intraperitoneally (IP) injected with vehicle or tunicamycin (2.5 mg/kg) for 18 h (n=5 per group replicated thrice); (b) iWAT or gWAT from mice IP injected with vehicle or tunicamycin (2.5 mg/kg) for 6, 12 or 18 h (n=5 per group replicated twice); (c) gWAT from mice after 12 wk of CD, HFD or HFD with TUDCA (250 mg/kg at 8am and 8pm, i.p., total 500 mg/kg for 15 days) (n=5 per group); (d) gWAT from mice after 4 or 8 wk of CD or HFD (n=5 per group). qPCR analysis of PPARγ or AP2 gene expression in (e) undifferentiated or differentiated gWAT or iWAT preadipocytes or adipocytes (n=3 per group replicated twice); (f) undifferentiated or differentiated human visceral or subcutaneous preadipocytes or adipocytes (n=3 per group replicated twice). All qPCR data are normalized with TBP and presented as mean ± SEM. Two-tailed student t-test, *,p<0.05; **,p<0.01; ***,p<0.001 (vs CD); #, p<0.01; ##,p<0.01 (vs HFD).

0

2

4

6

** *** ***

**

*

**

Il-1b Il-6 Ifnγ Tnfa Mcp1 F4/80 Crp Saa Sap

iWAT WT-Ctrl WT-Tuni KO-Ctrl KO-Tuni

a

b

Rel

ativ

e ex

pres

sion

/TB

P (A

.U)

0

1

2

*** *** * *** **

** ** **

Sap Il-1b Il-6 Ifnγ Tnfa Mcp1 Crp Saa

WT-Ctrl WT-Tuni

KO-Ctrl KO-Tuni

iWAT adipocytes

Rel

ativ

e ex

pres

sion

/TB

P (A

.U)

12 wk HFD gWAT iWAT

Il-1b Il-6 Ifnγ Tnfa Crp Saa Sap 0.0

0.5

1.0

1.5

*** *** *** * *

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

Pai-1

c

*** *** ***

*** *** **

***

***

12 wk HFD iWAT

Il-1b Il-6 Ifnγ Pai-1 Tnfa Crp Saa Sap 0.0

0.5

1.0

1.5 2.0 3.0 4.0 WT

KO

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

d

Supplementary Figure 3

Supplementary Figure 3. Expression of inflammatory and acute phase response markers in WAT qPCR analysis of inflammation and acute phase response markers gene expression in (a) iWAT from TRIP-Br2 WT or KO mice after 18 h of vehicle or tunicamycin (2.5 mg/kg, i.p.) treatment (n=5 per group replicated twice); (b) iWAT adipocytes differentiated from primary WT or KO SVF treated with or without tunicamycin (1 µg/ml) for 24 h (n=3 per group); (c) gWAT or iWAT from WT mice fed with 12 wk of HFD (n=6 per group replicated twice). (d) iWAT from WT or KO mice fed with 12 wk of HFD (n=6 per group replicated twice). All qPCR data are normalized with TBP and presented as mean ± SEM. Two-tailed student t-test, *,p<0.05; **,p<0.01; ***,p<0.001.

0

5

10

15 Creb3

***

GFP GFP-Creb3-V5

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

0

2

4

6

8

10

Chop

*** GFP Chop-V5

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

GFP

CR

EB

3-G

FP-V

5

GFP

CH

OP

-V5 �

140–

100–

70–

50–

40–

35–

25–

α-V5

Supplementary Figure 4

Supplementary Figure 4. Expression levels of CREB3 and CHOP qPCR analysis of CREB3 and CHOP in adipocytes overexpressing GFP control, CREB-GFP-V5 or CHOP-V5 (n=3 per group). All qPCR data are normalized with TBP and presented as mean ± SEM. Two-tailed student t-test, ***,p<0.001; Western blot analysis for CREB or CHOP levels using anti-V5 antibody in adipocytes overexpressing GFP control, CREB-GFP-V5 or CHOP-V5.

0

1

2

3

4

Trip-br2

Ctrl Tuni

pBabe- Neo

pBabe- mGATA3

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

b

* �

0

10

20

30 30 40 50 60

Nor

mal

ized

fold

enr

ichm

ent

Distal Proximal TRIP-Br2 promoter primers

*

*

d Ctrl-IgG Ctrl-Histone

0

20

40

60 *

Gata3 pBABE-Neo pBABE-GATA3

Rel

ativ

e ex

pres

sion

/TBP

(A.U

.)

a

0.0

0.5

1.0

1.5 Gata3fl/fl

Gata3

**

Rel

ativ

e ex

pres

sion

/TB

P (A

.U.)

Gata3KO

c

iWAT adipocytes

Supplementary Figure 5

Supplementary Figure 5. Role of GATA3 on TRIP-Br2 expression (a) qPCR analysis of GATA3 in gWAT adipocytes infected with control or GATA3 retrovirus (n=3 per group); (b) qPCR analysis of TRIP-Br2 in iWAT adipocytes infected with control or GATA3 retrovirus with or without tunicamycin treatment (n=3 per group). (c) qPCR analysis of GATA3 gene expression in gWAT adipocytes differentiated from GATA3fl/fl-CreERT2 primary SVF with or without tamoxifen (0.5 mM) treatment to induce GATA3 KO (n=5 per group). (d) qPCR analysis of proximal or distal genomic region of TRIP-Br2 transcript 3 promoter IgG (negative control) or anti-histone (positive control) immunoprecipitation (n=3 per group replicated twice). All qPCR data are normalized with TBP and presented as mean ± SEM. Two-tailed student t-test, *,p<0.05; **,p<0.01; ***,p<0.001.

BiP

TRIP-Br2

6h 24h 48h

C T C T C T

3T3-L1 adipocytes

6h 24h 48h

C T C T C T

3T3-L1adipocytes

Supplementary Figure 6

β-actin

6h 24h 48h

C T C T C T

3T3-L1adipocytes

Supplementary Figure 6. Uncropped images of blots shown in Figure 2f

Ctrl 6h 12h 18h

Tuni

Ctrl 6h 12h 18h

Tuni

gWAT iWAT

Ctrl 6h 12h 18h

Tuni

Ctrl 6h 12h 18h

Tuni

gWAT iWAT

BiP

TRIP-Br2

Ctrl 6 12 18

Tuni

Ctrl 6 12 18

Tuni gWAT iWAT

β-actin

Supplementary Figure 7

Supplementary Figure 7. Uncropped images of blots shown in Figure 3e

Supplementary Table 1: Compounds concentration for Figure 2a Compound Concentration TNFa 100 ng/ml MCP1 100 ng/ml IFNg 10 µg/ml IL6 2 µg/ml IL10 100 ng/ml BSA 0.5 M Palmitate 0.2 M Insulin 100 nM IL1β 25 ng/ml IL15 100 ng/ml CRP 200 ng/ml PAI-1 500 ng/ml Leptin 100 ng/ml Adiponectin 20 µg/ml

Supplementary Table 2. Primer sequences used in this study Gene Primer sequence

Forward: 5'- GCT CTC ACT CGT CGG GAT CC -3' mTrip-br2-tran1

Reverse: 5'- TGG CGC TGT AAG GTG TAA GAC -3' Forward: 5'- GAA GGC TTT GTG CAC GTG AGG -3' mTrip-br2-tran2

Reverse: 5'- TGG CGC TGT AAG GTG TAA GAC -3' Forward: 5'- GCT CCC TGC TAC CGT CGG C -3' mTrip-br2-tran3

Reverse: 5'- TGG CGC TGT AAG GTG TAA GAC -3' Forward: 5'- ATA TAT GTT GGG TAA AGG AGG AA -3' mTrip-br2-ORF

Reverse: 5'- TGG CGC TGT AAG GTG TAA GAC -3' Forward: 5'- TGG AGA GTG TGG ATC CCA AGC AA T-3' mIl-1b

Reverse: 5'- TGT CCT GAC CAC TGT TGT TTC CCA -3' Forward: 5'- ATC CAG TTG CCT TCT TGG GAC TGA -3' mIl-6

Reverse: 5'- TAA GCC TCC GAC TTG TGA AGT GGT -3' Forward: 5'- TCT GGA GGA ACT GGC AAA AG -3' mIfnγ

Reverse: 5'- TTC AAG ACT TCA AAG AGT CTG AGG -3' Forward: 5'- CCA CTC ACC TGC TGC TAC TCA T -3' mMcp-1

Reverse: 5'- TGG TGA TCC TCT TGT AGC TCT CC -3' Forward: 5'- GGG ACG AAA CTG GAG ATG TTA T -3' mPAI-1

Reverse: 5'- GAG GAG TTG CCT TCT CTT TCT C -3' Forward: 5'- GCC TCT TCT CAT TCC TGC TTG T -3' mTnfa

Reverse: 5'- GGC CAT TTG GGA ACT TCT CAT -3' Forward: 5'- GGC GGG CAC TGA ACT ATA AA -3' mCrp

Reverse: 5'- CGA GAC AAG GGA GAG AAT GTA ATC -3' Forward: 5'- CTA GGA ACA CTG AAG ATG CTC TC -3' mSaa1/2

Reverse: 5'- TCT CCT CCT CAA GCA GTT ACT A -3' Forward: 5'- TGT CTT CAC CAG CCT TCT TTC -3' mSap

Reverse: 5'- CTA GAT GTG GGA TCA GCT TCA C -3' Forward: 5'- TTT CCT CGC CTG CTT CTT C -3' mF4/80

Reverse: 5'- CCC CGT CTC TGT ATT CAA C -3' Forward: 5'- TTC AGC CAA TTA TCA GCA AAC TCT -3' mBiP

Reverse: 5'- TTT TCT GAT GTA TCC TCT TCA CCA GT -3' Forward: 5'- CCA CCA CAC CTG AAA GCA GAA -3' mChop

Reverse: 5'- AGG TGA AAG GCA GGG ACT CA -3' Forward: 5'- CTG AGT CCG AAT CAG GTG CAG -3' mXBP1s

Reverse: 5'- GTC CAT GGG AAG ATG TTC TGG -3' Forward: 5'- TTC CGG GAC AGA TTG GAT GTT GGA -3' mAtf4

Reverse: 5'- ATG GCC AAT TGG GTT CAC TGT CTG -3' Forward: 5'- CTG GGC TCG GTA GTT TGT ATC -3' mAtf6

Reverse: 5'- AGA CCT GAA TGG CTG CTT AC -3' Forward: 5'- CCA CTC TGG GAT CTT TCT TCA G -3' mCreb3

Reverse: 5'- AAA GAA GGG CTG TGG TTA GG -3' mGata1 Forward: 5'- ACT AAC TGT CAA ACG ACC ACT AC-3'

Reverse: 5'- TCA CCT GAT GGA GCT TGA AAT AG -3' Forward: 5'- GGA GAA AGG AGT AGG CAA GAA G -3' mGata2

Reverse: 5'- CCC AAG AAC ACA AAT AGC ACA C -3' Forward: 5'- AGC TGC CAG ATA GCA TGA AG -3' mGata3

Reverse: 5'- TAG GGC GGA TAG GTG GTA AT -3' Forward: 5'- ACC CTT CAC CAA TGA CTC CTA TG -3' mTbp

Reverse: 5'- ATG ATG ACT GCA GCA AAT CGC -3' mPparγ Forward: 5'- TCG CTG ATG CAC TGC CTA TG Reverse: 5'- GAG AGG TCC ACA GAG CTG ATT

Forward: 5'- TGA TGC CTT ATG GCA CTG GAC TCA-3' human TBP

Reverse: 5'- CTG CTG CCT TTG TTG CTC TTC CAA-3' Forward: 5'- GAC TCT CTG CCT GGG AAT TT -3' human TRIP-BR2-

ORF Reverse: 5'- GGA CGT ATC AAT GTC AGC AAA C -3' Forward: 5'- CTC GGA GGG TTT CTT GTT TCT -3' human GATA3

Reverse: 5'- CAG GAA TAG GGA CAA GAC AGA TG-3' Forward: 5'- AGA GTG AGA CTC CAC CTC AA -3' human BIP

Reverse: 5'- CAG CCA GTT GCC CAT CTA TAA -3' human PPARγ Forward: 5'- AGC CTC ATG AAG AGC CTT CCA Reverse: 5'- TCC GGA AGA AAC CCT TGC A human AP2 Forward: 5'- CGT CAC TTC CAC GAG AGT TTA T Reverse: 5'- TCC CAC AGA ATG TTG TAG AGT TC